Spanish plasma products maker Grifols SA (GRF.MC) said Monday its purchase of Talecris Biotherapeutics Holdings Corp. (TLCR) for $3.4 billion will boost its earnings per share by 30% from the second year following completion of the transaction.

In a Spanish regulatory filing, Grifols said its annual sales will rise to $2.8 billion following the purchase, 58% of which will come from North America and 28% from Europe.

-By Jonathan House, Dow Jones Newswires; +34 91 395 8120; jonathan.house@dowjones.com
Grifols (PK) (USOTC:GIKLY)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024 Plus de graphiques de la Bourse Grifols (PK)
Grifols (PK) (USOTC:GIKLY)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024 Plus de graphiques de la Bourse Grifols (PK)